Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial
- PMID: 21036355
- DOI: 10.1016/j.atherosclerosis.2010.09.013
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial
Abstract
Objective: To determine the effects of statin treatment and omega-3 polyunsaturated fatty acid supplementation on plasma plant sterol concentrations and cholesterol synthesis in patients with type 2 diabetes.
Methods: Plant sterol concentrations and lanosterol (a marker of cholesterol synthesis) were measured using a high sensitivity assay to assess the effect of double-blind daily treatment for 4 months with atorvastatin 20mg or placebo and, in a 2 × 2 factorial design, omega-3 ethyl esters 90 2g or placebo.
Results: 658 patients were included in a per protocol analysis. The 4 treatment groups had similar mean [SD] age (63.5 years [11.7]), HbA(1c) (6.9% [1.1]) and diabetes duration (median 4 years [inter-quartile range 2, 8]). Atorvastatin treatment alone reduced low density lipoprotein (LDL) cholesterol by 1.4 mmol/l (44%, p<0.001), triglycerides by 0.3 mmol/l (20%, p<0.0001) and lanosterol by 0.36 μmol/l (72%, p<0.001). There was no significant placebo adjusted change in median [95% confidence intervals] total plant sterol concentrations (-0.77 μmol/l [inter-quartile range -2.13, 0.59]), although they were increased significantly with omega-3-acid EE90 treatment (3.23 μmol/l [1.28, 5.17]). There was a 27% smaller reduction in LDL cholesterol with atorvastatin treatment in low cholesterol synthesisers with high absorption, defined by changes at or above the median lanosterol and campesterol levels, respectively, compared with the obverse group (difference 0.42 mmol/l [0.21, 0.62]).
Conclusion: Treatment with atorvastatin in type 2 diabetes did not change median total plasma plant sterol concentrations, but LDL cholesterol was reduced most efficaciously in high cholesterol synthesisers with low intestinal cholesterol absorption.
Clinical trial registration information: Current controlled trials number ISRCTN: 76737502 (http://isrctn.org).
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.Diabetologia. 2009 Jan;52(1):50-9. doi: 10.1007/s00125-008-1179-5. Epub 2008 Nov 11. Diabetologia. 2009. PMID: 19002433 Clinical Trial.
-
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.J Clin Lipidol. 2011 Nov-Dec;5(6):483-92. doi: 10.1016/j.jacl.2011.09.001. Epub 2011 Sep 13. J Clin Lipidol. 2011. PMID: 22108152 Clinical Trial.
-
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.Diabetes Care. 2001 Aug;24(8):1335-41. doi: 10.2337/diacare.24.8.1335. Diabetes Care. 2001. PMID: 11473066 Clinical Trial.
-
Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.Nutr Metab Cardiovasc Dis. 2001 Feb;11(1):7-16. Nutr Metab Cardiovasc Dis. 2001. PMID: 11383326 Clinical Trial.
-
Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.Drugs. 2009 May 29;69(8):1077-105. doi: 10.2165/00003495-200969080-00008. Drugs. 2009. PMID: 19496632 Review.
Cited by
-
Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD012345. doi: 10.1002/14651858.CD012345.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 Nov 27;11:CD012345. doi: 10.1002/14651858.CD012345.pub3. PMID: 30019767 Free PMC article. Updated.
-
Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis.Diabetologia. 2014 Dec;57(12):2444-52. doi: 10.1007/s00125-014-3374-x. Epub 2014 Sep 23. Diabetologia. 2014. PMID: 25245638
-
Effects of Omega-3 Fatty Acid Supplementation on Glucose Control and Lipid Levels in Type 2 Diabetes: A Meta-Analysis.PLoS One. 2015 Oct 2;10(10):e0139565. doi: 10.1371/journal.pone.0139565. eCollection 2015. PLoS One. 2015. PMID: 26431431 Free PMC article.
-
Could nutrient supplements provide additional glycemic control in diabetes management? A systematic review and meta-analysis of randomized controlled trials of as an add-on nutritional supplementation therapy.Arch Pharm Res. 2022 Mar;45(3):185-204. doi: 10.1007/s12272-022-01374-6. Epub 2022 Mar 18. Arch Pharm Res. 2022. PMID: 35304727
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD003177. doi: 10.1002/14651858.CD003177.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 Nov 30;11:CD003177. doi: 10.1002/14651858.CD003177.pub4. PMID: 30019766 Free PMC article. Updated.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous